✦ LIBER ✦

Quality of life in stiff person syndrome

✍ Scribed by Willibald Gerschlager; Anette Schrag; Peter Brown

Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 75 KB
Volume: 17
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.10235

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Stiff person syndrome (SPS) is a rare, chronic disorder characterized by painful spasm and stiffness. We investigated the quality of life (QoL) in SPS patients, and identified factors associated with impairment in patients' QoL. Twenty‐four SPS patients (10 men, 14 women; mean age ± S.D., 52.6 ± 9.5 years) completed the medical outcomes study Short Form health survey (SF‐36), the Beck Depression Inventory (BDI), and a questionnaire asking for sociodemographic and clinical details. Extent of the disease was assessed using a distribution of stiffness score. SPS patients showed markedly reduced mean scores for all dimensions of the SF‐36 when compared to norms from the general population of the United Kingdom. QoL scores showed a strong correlation with the extent of the disease. Depression was a common finding; 14 of 24 patients had depressive symptoms as evidenced by the BDI. There was a significant and strong correlation between the BDI score and several SF‐36 subscores. This is the first study to address QoL in patients with SPS. We have shown that SPS has a significant impact on patients' reported QoL. The association between depression and QoL highlights the importance of recognizing and treating depression in SPS. © 2002 Movement Disorder Society

📜 SIMILAR VOLUMES

Effect of treatment with intravenous imm

Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff-person syndrome

✍ Willibald Gerschlager; Peter Brown 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB

The therapeutic effects of intravenous immunoglobulin (IVIG) on the stiff-person syndrome (SPS) have been described exclusively in case reports or open-label studies in terms of clinical outcomes. We investigate whether IVIG improves quality of life (QoL) in the SPS. Six patients with the classic fo

PET evidence of central GABAergic change

PET evidence of central GABAergic changes in stiff-person syndrome

✍ Daniela Perani; Valentina Garibotto; Andrea Panzacchi; Rosa Maria Moresco; Paola 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

## Abstract We measured expression of central nervous system GABA‐A receptors with ^11^C‐flumazenil (^11^C‐FMZ) and PET in two subjects with stiff person syndrome (SPS). We found reduced ^11^C‐FMZ binding potential (BP) in motor‐premotor cortex, and increased ^11^C‐FMZ BP in the cerebellar nuclei.

A therapeutic trial of milacemide in myo

A therapeutic trial of milacemide in myoclonus and the stiff-person syndrome

✍ P. Brown; P. D. Thompson; J. C. Rothwell; B. L. Day; Prof. C. D. Marsden 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 269 KB 👁 1 views

We investigated the therapeutic effects of milacemide in seven patients with myoclonus and three patients with the stiff-person syndrome in an open-label trial. Milacemide was initiated at 800 mg/day and was gradually increased to a maximum dosage of 2,400 mg/day. No significant improvement occurred

Botulinum toxin a improves muscle spasms

Botulinum toxin a improves muscle spasms and rigidity in stiff-person syndrome

✍ Dr. Rocco Liguori; Carla Cordivari; Elio Lugaresi; Pasquale Montagna 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB

We studied the effect of botulinum toxin A (BTA) on painful muscular spasms and rigidity in two bedridden patients with clinical, electrophysiologic, and immunologic evidence of stiff-person syndrome. We injected BTA or saline solution into several limb muscles with both the rater and patient blinde

Pathological findings in a case of stiff

Pathological findings in a case of stiff person syndrome with anti-GAD antibodies

✍ Jonathan Witherick; J. Robin Highley; Marios Hadjivassiliou 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 1023 KB

Posterior cortical atrophy (PCA) represents a degenerative disorder characterized by the development of higherorder visual deficit. 1 PCA may result from heterogeneous pathologies that make up tauopathies. An increasing number of mutations in the tau gene (microtubule-associated protein tau [MAPT])

Significant improvement of stiff-person

Significant improvement of stiff-person syndrome after paraspinal injection of botulinum toxin A

✍ Dave Davis; Dr. Bahman Jabbari 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 356 KB

## Abstract Following several months of low back pain, a 36‐year‐old developed progressive stiffness of the abdominal, low back, and thigh muscles. On examination, these muscles demonstrated marked hypertonia consistent with the clinical diagnosis of stiff‐person syndrome. The patient demonstrated